FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of FibroGen in a report on Thursday, February 20th.

FibroGen Stock Up 2.9 %

Shares of FibroGen stock opened at $0.44 on Friday. The company has a market cap of $44.27 million, a PE ratio of -0.36 and a beta of 0.82. The business has a 50 day moving average of $0.51 and a 200 day moving average of $0.43. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80.

Institutional Investors Weigh In On FibroGen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. FMR LLC grew its stake in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the period. Geode Capital Management LLC grew its stake in FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the period. JPMorgan Chase & Co. grew its stake in FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares during the period. Franklin Street Advisors Inc. NC grew its stake in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares during the period. Finally, Renaissance Technologies LLC grew its stake in FibroGen by 80.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares during the period. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.